- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05016466
GOLD 0 - DLCO 1: A Look Beyond the Obstruction. Is Spirometry Enough for COPD (Chronic Obstructive Pulmonary Disease) Screening?
GOLD 0 - DLCO 1: A Look Beyond the Obstruction. Is Spirometry Enough for COPD Screening?
This is a multicenter observational prospective study in smokers or ex-smokers with cumulative exposure ≥ 10 a / p (years / pack) with respiratory symptoms and presenting a normal spirometry.
The patients who sign the corresponding informed consent, will undergo a DLCO and will be divided into two groups according to the result:
- Group I. Patients with DLCO <80%.
- Group II Patients with DLCO≥80%.
Both groups will be followed for 5 years.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Cruz González, PhD
- Numéro de téléphone: 0034961973677
- E-mail: cruz.gonzalez@uv.es
Lieux d'étude
-
-
Valencian Community
-
Valencia, Valencian Community, Espagne, 46010
- Hospital Clínico Universitario de Valencia
-
Contact:
- cruz Gonzalez, PhD
- Numéro de téléphone: 0034961973977
- E-mail: cruz.gonzalez@uv.es
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥18 years. The participant or his / her legal representative is willing and able to give informed consent to participate in the study.
- Female or male patients with age equal to or greater than 18 years.
- Smokers or ex-smokers with cumulative exposure ≥ 10 a / p
- Respiratory symptoms
- Normal spirometry.
Exclusion Criteria:
- Age under 18 years.
- Participation in another clinical study.
- Patients with a life expectancy of less than 2 years due to neoplasms or other serious systemic diseases.
- Refusal to sing informed consent.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Group I. Patients with DLCO <80%.
Patients with DLCO <80% will be followed at baseline and once a year during the study
|
Patients will followed during 5 years, Annual follo-up visits will be carried out during this period
|
Group II. Patients with DLCO ≥ 80%.
Patients with DLCO ≥80% only will be followed at baseline and year 5.
|
Patients will followed during 5 years, and only 2 visits , baseline and 5 years
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Changes from baseline of Diffusion Capacity (DLCO) at 5 years
Délai: through study completion, an average of 5 years
|
To determine the value of DLCO in COPD screening in smokers and ex-smokers with respiratory symptoms and normal spirometry (GOLD 0)
|
through study completion, an average of 5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Risk factors associated to the development of COPD
Délai: through study completion, an average of 5 years
|
Risk factors associated to the development of COPD
|
through study completion, an average of 5 years
|
Changes from baseline of inflammatory Markers at 2 and 5 years
Délai: 2 and 5 years
|
To Study soluble receptors involved in inflammation processes and tissue repair in early disease stages.
|
2 and 5 years
|
Oxidative stress
Délai: through study completion, an average of 5 years
|
To Study of oxidative stress parameters in early disease stages
|
through study completion, an average of 5 years
|
Diffusion study
Délai: through study completion, an average of 5 years
|
To Characterize patients in stage 0 of GOLD with impaired diffusion
|
through study completion, an average of 5 years
|
Changes from baseline of High Resolution Computed Tomography (HRTC) at 5 years
Délai: Baseline and 5 years
|
To determine changes in HRCT to identify subgroups of patients with different clinical and evolutionary trajectories
|
Baseline and 5 years
|
Airflow limitation Study
Délai: through study completion, an average of 5 years
|
To Investigate the contribution of measuring lung volumes for the diagnosis of COPD when there is no evidence of airflow limitation in spirometry (GOLD 0).
|
through study completion, an average of 5 years
|
Gender differences in value of diffusion (DLCO)
Délai: through study completion, an average of 5 years
|
To assess if there are differences between men and women with diffusion disorder
|
through study completion, an average of 5 years
|
Childhood background
Délai: Baseline
|
To assess whether factors, such as the effect of lung development during childhood and adolescence, bronchial hyperreactivity and / or the role of infections influences the risk of developing the disease or its progression.
|
Baseline
|
Comorbidity
Délai: through study completion, an average of 5 years
|
To characterize the comorbidities associated with GOLD 0 patients and altered diffusion.
|
through study completion, an average of 5 years
|
Collaborateurs et enquêteurs
Les enquêteurs
- Directeur d'études: Cruz González, PhD, Hospital Clínico Universitario de Valencia
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GOLD 0-DLCO 1
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .